Capsazepine antagonizes TRPV1 activation induced by thermal and osmotic stimuli in human odontoblast-like cells

Cepeda, Lilia Jadith Bernal; Velandia-Romero, Myriam L.; Castellanos, Jaime E.

doi:10.1016/j.jobcr.2022.11.003

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CZP (Tocris, Bristol, UK) reconstituted in dimethyl sulfoxide (DMSO; Merck Millipore, Burlington, MA, USA) was used as the active compound, and working solutions were developed using sterile water. CZP loading was carried out using sorption (adsorption and desorption) [ 23 ], and the loading concentration was determined using a previously established 50% cytotoxic concentration of CZP on OLCs [ 24 ]. Taking into account the burst effect of these delivery systems, which corresponds to 20–30% of the initial load, the nanogels were loaded with 133 μM of CZP in sterile water.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels

Bernal-Cepeda,

Jiménez,

Velandia-Romero

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The modulation of TRPV1 emerges as a promising strategy for dental pain management. This study aimed to assess TRPV1 modulation in a human odontoblast-like cell model using Capsazepine (CZP) loaded in a nanogel delivery system. Gelatin nanogels, synthesized via the emulsification-gelation technique, were characterized and loaded with the TRPV1 antagonist, CZP. HPLC determined a remarkable 67.5 ± 0.04% CZP loading efficiency, with 71.7% of nanogels falling within the 300–950 nm size range, as evidenced by light microscopy. Moreover, CZP-loaded nanogels had a low cytotoxicity. An FTIR analysis showed no adverse chemical interactions, ensuring stability and active release. When examining biological responses, TRPV1 expression and channel activity were assessed in odontoblast-like cells. On the fifth day post-treatment, cells treated with CZP-loaded nanogels exhibited an increased TRPV1 expression and a reduction in calcium fluxes after agonist stimulus (F/F0 ratio 1.18 ± 0.18), resembling the response in free CZP-treated cells (1.28 ± 0.15). A two-way analysis of variance and the Tukey’s test were used to determine statistical significance (p < 0.05). This delivery system, proven to be economical and straightforward, holds promise for dental pain management and potential local use. Local administration minimizes systemic adverse effects, making it a practical solution for releasing molecules in the oral cavity.

show abstract

Section: Methodsmentioning

confidence: 99%

“…These cells were previously isolated from consenting healthy donors. In the case of OLCs, their characterization included assessing dentin sialophosphoprotein and dentin matrix acidic phosphoprotein expression [ 24 ], while for HGF, vimentin expression was evaluated.…”

Section: Methodsmentioning

confidence: 99%

Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels

Bernal-Cepeda,

Jiménez,

Velandia-Romero

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

Design and experimental validation of a new radiolabeled analog of N-(3-hydroxy-4-methoxy-phenyl-methyl) ferrocene-carboxamide (VFC) targeting the TRPV1 receptor

Dallegi,

Ben Hassen,

Rached

et al. 2024

European Journal of Medicinal Chemistry Reports

View full text Add to dashboard Cite

Intraplantar Injection of Monosodium Iodoacetate Produces Hyperalgesia in Rats and the Mechanism Underlying the Effect

Li,

Yao,

et al. 2024

JBM

View full text Add to dashboard Cite

Objective: To observe the effect of intraplantar injection of monosodium iodoacetate (MIA) on pain perception in rats and to investigate the role of transient receptor potential vanilloid type 1 (TRPV1) in the effect. Methods: Adult male Wistar rats were used in the experiment. 1) MIA was injected subcutaneously into the right hindpaw of rats, the low, medium, and high doses of MIA were 0.11, 0.33, and 1 mg, respectively, then the changes of paw withdrawal thermal latency, paw withdrawal mechanical threshold, and dynamic weight bearing within 4 hours after MIA injection were measured. 2) Capsazepine (TRPV1 antagonist, 30 μg) was injected subcutaneously into the right hindpaw of rats at 2 hours after intraplantar injection of MIA (1 mg), then the changes of paw withdrawal thermal latency, paw withdrawal mechanical threshold, and dynamic weight bearing within 1 hour after capsazepine injection were measured. Results: 1) The paw withdrawal thermal latency, paw withdrawal mechanical threshold, and dynamic weight bearing decreased after intraplantar injection of MIA in rats and the effect lasted for at least 4 hours. 2) The MIA-induced reduction in paw withdrawal thermal latency, paw withdrawal mechanical threshold, and dynamic weight bearing were significantly alleviated after intraplantar injection of capsazepine in rats. Conclusion: Intraplantar injection of MIA can produce thermal pain, mechanical pain, and spontaneous pain for more than 4 hours, which may be due to the TRPV1 activation caused by MIA.

show abstract

Capsazepine antagonizes TRPV1 activation induced by thermal and osmotic stimuli in human odontoblast-like cells

Cited by 3 publications

References 28 publications

Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels

Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels

Design and experimental validation of a new radiolabeled analog of N-(3-hydroxy-4-methoxy-phenyl-methyl) ferrocene-carboxamide (VFC) targeting the TRPV1 receptor

Intraplantar Injection of Monosodium Iodoacetate Produces Hyperalgesia in Rats and the Mechanism Underlying the Effect

Contact Info

Product

Resources

About